Goodvastatin F Tablet is a combination lipid-lowering medication containing Atorvastatin 10 mg and Fenofibrate 160 mg. It is primarily indicated for the management of dyslipidemia, including mixed hyperlipidemia and hypertriglyceridemia, where monotherapy with either agent is insufficient. Atorvastatin, a selective HMG-CoA reductase inhibitor, reduces cholesterol synthesis in the liver, leading to decreased low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels, while modestly increasing high-density lipoprotein cholesterol (HDL-C). Fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptors (PPARα), enhancing lipolysis and elimination of triglyceride-rich particles, thereby effectively lowering serum triglycerides and increasing HDL-C. The combined action of these agents offers a complementary mechanism to improve lipid profiles and reduce cardiovascular risk in patients with mixed dyslipidemia. Goodvastatin F Tablet should be administered once daily, preferably with food to enhance absorption. It is essential to monitor liver function tests, renal function, and lipid levels periodically during therapy. Caution is advised in patients with hepatic or renal impairment, and potential adverse effects include myopathy, hepatotoxicity, and gastrointestinal disturbances. This combination therapy should be used under medical supervision as part of a comprehensive cardiovascular risk reduction strategy, including diet and lifestyle modifications.